PP-155 Advances in research on the role of transforming growth factor-β1 in liver fibrosis  by Dang, S.-S. & Li, Y.-P.
Poster Presentations S73
PP-155 Advances in research on the role of
transforming growth factor-b1 in liver ﬁbrosis
S.-S. Dang1 *, Y.-P. Li1. 1Department of Infectious Disease,
the Second Afﬁliated Hospital, School of Medicine, Xi’an
Jiaotong University, Xi’an 710004, Shaanxi Province,
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Transforming growth factor-b1 (TGF-b1) is one of the most
key dominant cytokines leading to liver ﬁbrosis, which
is most closely to the occurrence and development of
liver ﬁbrosis and extracellular matrix (ECM) metabolism.
Scholars have demonstrated that TGF-b1 plays a signiﬁcant
role in the occurrence and development of live ﬁbrosis
from a large number of studies, what is more important
they have proposed novel approaches to the treatment of
hepatic ﬁbrosis in recent years, and have gained encouraged
progress especially in gene therapy and immunotherapy.
This article provides an overview of the latest developments
in research on the role of TGF-b1 in liver ﬁbrosis mechanism
and treatment brieﬂy.
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Background: Diabetes mellitus and hepatitis C are
interrelated with each other because of the natural history
of the disease and chronic complications if hepatitis C.
With the passage of time, these two problems are much
frequently seen in the Hepatology clinics and creating
a health burden. The study aim was to evaluate the
frequency and epidemiological nature of HCV infection
among Pakistani patients already diagnosed as cases of
diabetes mellitus.
Methods: Study was conducted at Sughra diabetic clinic,
Pakistan over a period of 6 months from March 2009 to
September 2009. 100 Diabetic patients visiting the out
patient clinics were recruited. Mean age 43±8 years.
57% were males. Brief case history of the patients, clinical
examination and laboratory investigations were taken in
to consideration. Diabetes mellitus was conﬁrmed by 2
fasting plasma glucose levels >126mg/dL or 2 random plasma
glucose levels >200mg/dL while hepatitis C was conﬁrmed
by ELISA kit method.
Results: 43% (n = 43) patients were found to be positive for
hepatitis C (Anti-HCV+) and all of them had type 2 diabetes.
There was no gender difference in the seropositive cases.
ALT (Alanine aminotransferase) levels were above normal
among 80% of the positive cases as compared to the 20%
of the seronegative patients. The seropositive cases had a
comparatively higher blood sugar level.
Conclusion: The frequency of hepatitis-C is more among
patients with type 2 Diabetes mellitus and usually
complicates the disease. It’s an upcoming challenge for
the hepatologists as well as for endocrinologists to treat
these simultaneous diseases accordingly. Liver enzymes are
much raised in cases where these two diseases occur
simultaneously and efforts should be made to treat the
disease on individual basis while keeping in mind the
epidemiological facts.
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Objective: To investigate the incidence of osteopenia and
osteoporosis in patients with HBV liver cirrhosis and analyze
related factors.
Methods: The bone mineral density (BMD) values of 32
patients with hepatitis B cirrhosis (mean age 53.4±11.2 yrs)
and 40 healthy controls (mean age 53.3±10.8 yrs) were
measured by French dual-energy X-ray absorptiometry and
retrospectively analyzed.
Results:
1. There are 9 cases with osteoporosis and 14 cases with
osteopenia in 32 cirrhosis patients. In controls there are
only one with osteoporosis and 7 cases with osteopenia.
There was a signiﬁcant difference in incidence of BMD
abnormality between the two groups (P< 0.05).
2. The BMD of cirrhosis patients and control cases are listed
in Table 1. The BMD of hip joint and lumbar vertebra in
Child Pugh C cirrhosis patients were lower than Child
Pugh A cirrhosis patients (P< 0.05), were much lower
than healthy control group (P< 0.01).
3. The Child Pugh scores and serum calcium were
correlated with BMD in patients with HBV liver cirrhosis
(P< 0.05).
Conclusion: Patients with HBV liver cirrhosis are more easier
to suffer with osteoporosis and osteopenia than healthy
cases. Child Pugh C cirrhosis patients should be suggested
to accept a routine BMD measurement.
Table 1. Bone mineral density of cirrhosis group and control group
Group Cases Osteo-
penia
Osteo-
porosis
BMD of
hip joint
(g/cm2)
BMD of
lumbar
vertebra
(g/cm2)
Cirrhosis group 32 14* 9* 0.78±1.13 0.83±0.16
Child A 14 3 3 0.83±0.13 0.91±0.18
Child B 11 7 3 0.76±0.13 0.79±0.09
Child C 7 4 3 0.72±0.13**# 0.71±0.13**#
Healthy controls 40 7 1 0.92±0.10 1.03±0.14
*Compared with the control group, P < 0.05, chi-square value 5.93, 9.76;.
**Compared with the control group, P < 0.01, t value: 4.75, 5.69.
#Compared with Child A cirrhosis patients, P < 00.05, t value:
1.91, 2.61.
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Objective: To evaluate effect of Xuebijing injection in
patients of Liver Cirrhosis (LC) with spontaneous bacterial
peritonitis (SBP).
Methods: 66 LC patients with SBP were divided into two
groups randomly. 34 patients in control group were given
supported care and treated with liver protecting drugs,
third generation cephalosporin. Besides these treatments
on the control group, 32 patients in study group were given
Xuebijing injection (50ml/d) additionally. The symptoms
